1. Juvenile idiopathic arthritis;Ravelli A;Lancet,2007
2. Polyarticular juvenile idiopathic arthritis ‐ epidemiology and management approaches;Oberle EJ;Clin Epidemiol,2014
3. Bristol‐Myers Squibb Canada.ORENCIA® (abatacept) product monograph. Prepared June 26 2006. Approved September 9 2019. URL:https://www.bms.com/assets/bms/ca/documents/productmonograph/ORENCIA_EN_PM.pdf.
4. Bristol‐MyersSquibb.Orencia prescribing information Reference ID 4118896. 2017. URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125118s209lbl.pdf.
5. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis;Haggerty HG;J Rheumatol,2007